Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:United_States_federal_law
|
| gptkbp:amendedBy |
gptkb:Federal_Food,_Drug,_and_Cosmetic_Act
gptkb:Patent_Act_of_1952 |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:enactedBy |
gptkb:98th_United_States_Congress
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pub.L. 98–417
|
| gptkbp:officialName |
gptkb:Drug_Price_Competition_and_Patent_Term_Restoration_Act
|
| gptkbp:popularFor |
gptkb:Hatch-Waxman_Act
|
| gptkbp:publicLawNumber |
98-417
|
| gptkbp:purpose |
to encourage the manufacture of generic drugs
to provide patent term extensions for brand-name drugs to streamline FDA approval for generics |
| gptkbp:signedBy |
gptkb:Ronald_Reagan
September 24, 1984 |
| gptkbp:sponsor |
gptkb:Henry_Waxman
gptkb:Orrin_Hatch |
| gptkbp:statutesAtLargeCitation |
gptkb:98_Stat._1585
|
| gptkbp:subject |
gptkb:US_patent
gptkb:drug generic drugs |
| gptkbp:bfsParent |
gptkb:Drug_Price_Competition_and_Patent_Term_Restoration_Act
|
| gptkbp:bfsLayer |
8
|